Introduction
Patients presenting with laryngopharyngeal symptoms (LPS) are frequently treated empirically with proton pump inhibitors (PPIs) without objective evidence of pathological reflux. It remains uncertain whether oesophageal motility phenotypes observed on high-resolution manometry (HRM) are associated with PPI response in this population, and whether motility assessment could help identify those most likely to benefit from acid suppression.
Aims & Methods
This retrospective two-centre study included 200 patients referred for oesophageal physiology with ≥2 laryngopharyngeal symptoms (e.g., cough, throat clearing, excess phlegm, dysphonia, throat pain). HRM and 24-hour pH-impedance studies were performed in line with current guidance. Those with confirmed laryngopharyngeal reflux disease (LPRD) were excluded. The remaining 154 patients were classified as PPI responders (partial/complete) or non-responders based on reporting at time of appointment. Oesophageal function was categorised as normal or abnormal (absent contractility, hypotensive motility, hypercontractility and oesophagogastric outflow obstruction (OGJOO)) in line with the Chicago Classification v4.0, using a protocol of single water swallows and a rice meal. Symptom severity and hypervigilance were assessed using the Laryngeal Cognitive-Affective Tool (LCAT) and the Esophageal Hypervigilance and Anxiety Scale (EHAS).
Results
Of 154 patients with LPS and without pathological oesophageal acid exposure, 57 (37%) were PPI responders and 97 (63%) were non-responders. Abnormal oesophageal function was significantly more common among responders (24/57; 42%) than non-responders (9/88; 10%) (p<0.001). No significant differences were observed between groups in any HRM metrics beyond motility classification, or in reflux parameters on pH-impedance monitoring. Symptom severity scores on both the LCAT and EHAS were comparable between responders and non-responders.
Table 1 – Demographics and physiological metrics of PPI responders vs non-responders in patients with LPS.
| Metrics | Responders (n=57) | Non-responders (n=97) | p-value |
| Median Age | 54 | 52 |
|
| N Female (%) | 33 (58%) | 59 (61%) |
|
| Normal motility | 33 | 88 | <0.001 |
Abnormal motility Hypotensive motility Hypercontractility OGJOO Absent contractility | 24 12 7 3 2 | 9 5 3 1 0 |
|
| Median LOS tone (mmHg) | 26.0 | 25.5 | 0.53 |
| Median AET (%) | 1.2 | 0.8 | 0.99 |
| Median no. of reflux events | 31 | 27 | 0.22 |
| Median no. of proximal reflux | 10 | 8 | 0.76 |
| Median MNBI | 1766 | 1967 | 0.15 |
Conclusion
In patients with laryngopharyngeal symptoms and without objective evidence of pathological reflux, response to PPI therapy appears to be more closely associated with oesophageal function than reflux burden or symptom severity. These findings suggest that oesophageal motor dysfunction may be a key driver of symptom generation and treatment response in this population, challenging a reflux-centric model of LPS. High-resolution manometry may therefore have a role in stratifying patients and guiding empirical PPI therapy.